The FDA should restrict barzolvolimab to a last-line therapy for chronic hives

FDA approvals, clinical trial design, psychedelic drug policy, compounding pharmacy regulation, and drug scheduling.

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Monitoring and prevention of adverse effects from medications.

Immune responses to substances that may range from mild, localized symptoms to severe, life-threatening reactions.